https://orcid.org/0000-0003-4845-4119
References
- Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251. doi:10.1038/s41581-020-0268-7
- Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M;Alberta Kidney Disease Network FT. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA. 2008;299(7):793–805. doi:10.1001/jama.299.7.793
- Nashwan AJ, Yassin MA, Mohamed Ibrahim MI, Abdul Rahim HF, Shraim M. Iron overload in chronic kidney disease: less ferritin, more T2* MRI. Front Med. 2022;9:865669. doi:10.3389/fmed.2022.865669
- Nashwan AJ, Yassin MA, Abd‐Alrazaq A, et al. Hepatic and cardiac iron overload quantified by magnetic resonance imaging in patients on hemodialysis: a systematic review and meta‐analysis. Hemodial Int. 2023;27(1):3–11. doi:10.1111/hdi.13054
- Taher A, El‐Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465. doi:10.1111/j.1600-0609.2009.01228.x
- Choudhry VP, Naithani R. Current status of iron overload and chelation with deferasirox. Indian J Pediatr. 2007;74(8):759–764. doi:10.1007/s12098-007-0134-7
- Shah NR. Advances in iron chelation therapy: transitioning to a new oral formulation. Drugs Context. 2017;2017:6.
- Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev. 2008;22:S35–41. doi:10.1016/S0268-960X(08)70007-9
- Sato T, Kobune M, Murase K, et al. Iron chelator deferasirox rescued mice from Fas‐induced fulminant hepatitis. Hepatol Res. 2011;41(7):660–667. doi:10.1111/j.1872-034X.2011.00821.x
- Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology. 2013;18(3):188–193. PMID: 23332024. doi:10.1111/nep.12035
- Chen CH, Shu KH, Yang Y. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload. Hematology. 2015;20(5):304–310. PMID: 25200910. doi:10.1179/1607845414Y.0000000199
- Yii E, Doery JC, Kaplan Z, Kerr PG. Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients. Nephrology. 2018;23(9):887–889. PMID: 29663590. doi:10.1111/nep.13389
- Yusuf B, McPhedran P, Brewster UC. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis. 2008;52(3):587–590. PMID: 18534729. doi:10.1053/j.ajkd.2008.03.034
- Beydoun HG, Saliba AN, Taher AT. Deferasirox in thalassemia patients with end‐stage renal disease. Am J Hematol. 2016;91(10):E456–7. doi:10.1002/ajh.24457
- Bekhechi W, Chiali H, Khelil L, Sari-Hamidou R, Benmansour M. Hemosiderosis in chronic dialysis patients: monitoring the response to deferasirox by quantitative hepatic magnetic resonance imaging. Hemodial Int. 2023;27(3):270–277. doi:10.1111/hdi.13081
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Nino MD, Villarrubia J, Ortiz A. Deferasirox nephrotoxicity—the knowns and unknowns. Nat Rev Nephrol. 2014;10(10):574–586. doi:10.1038/nrneph.2014.121
- Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: pathophysiology and pharmacology. Trend Pharmacol Sci. 2021;42(8):640–656. doi:10.1016/j.tips.2021.05.001
- Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329–342. doi:10.2165/00019053-200725040-00005